Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsGold Coast BLENREP Prior Auth Coverage | OpenPayer
    Ask Trek AI about this page
    CurrentGold Coast Health PlanPolicy N/A

    BLENREP (belantamab mafodotin-blmf) Coverage for Relapsed or Refractory Multiple Myeloma

    Customize your policy alerts

    Sign up for all goldcoasthealthplan policy alerts

    Know when goldcoasthealthplan releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Prior authorization and Part B coverage for physician-administered intravenous BLENREP in adult members with relapsed or refractory multiple myeloma, including requirements for prior therapy, dosing, administration setting, documentation, monitoring, and authorization duration.

    Policy Summary
    PayerGold Coast Health Plan
    PolicyBLENREP (belantamab mafodotin-blmf) Coverage for Relapsed or Refractory Multiple Myeloma
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateFeb 12, 2026
    Last ReviewFeb 12, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization documentation confirming adult relapsed or refractory multiple myeloma, at least two prior therapy lines including a proteasome inhibitor and an immunomodulatory agent, and oncologist involvement.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    ≥2Prior lines of therapy required
    2.5 mg/kgMaximum labeled dose

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Q3 weeks
    Labeled dosing interval
    6 monthsInitial authorization
    12 monthsReauthorization
    REMSREMS required

    BLENREP Coverage Criteria

    Initial BLENREP Coverage

    Covered when all of the following are met:

    BLENREP approval criteria

    • Administration: BLENREP is administered as a physician-administered intravenous infusion in an office or hospital outpatient department and is not self-administered.
    • Diagnosis: The patient has relapsed or refractory multiple myeloma.
    • Prior therapy: The patient has received at least two prior lines of therapy, including both a proteasome inhibitor and an immunomodulatory agent.At least 2 prior lines; must include both drug categories

      Examples include bortezomib or Kyprolis as proteasome inhibitors and pomalidomide or Revlimid as immunomodulatory agents.

    • Prescriber specialty: BLENREP is prescribed by or in consultation with an oncologist.
    • Age: The patient is an adult.≥18 years
    • Dose or supported off-label use

      • Labeled dose: The dose does not exceed 2.5 mg/kg using actual body weight every three weeks, or every 21-day cycle.≤2.5 mg/kg actual body weight every 21 days
      • Supported off-label use: The dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use, and the prescriber submits supporting evidence.

    Coverage is available for physician-administered intravenous BLENREP in an office or hospital outpatient department; it is not eligible for self-administration. The member must be an adult aged 18 years or older with relapsed or refractory multiple myeloma, have received at least two prior lines of therapy including a proteasome inhibitor and an immunomodulatory agent, and receive treatment prescribed by or provided in consultation with an oncologist.

    Billing and Coding

    BLENREP NDCNDC
    0173-0913-0110-digit NDC
    00173-0913-0111-digit NDC
    HCPCS CodesHCPCS
    J9999Not otherwise classified, antineoplastic drugs
    J3590Unclassified biologics
    C9399Unclassified drugs or biologics
    CPT Procedural CodesCPT
    96413Chemotherapy IV infusion, up to 1 hour

    Authorization and Documentation Requirements

    Prior Authorization

    BLENREP Prior Authorization Required

    Prior authorization is required for BLENREP. Submit a complete request documenting the indication, administration plan, patient eligibility, prior therapy, prescriber qualifications, dose, and any applicable off-label support.

    • Physician-administered IV infusion; self-administration is not permitted.
    • Document relapsed or refractory multiple myeloma, prior treatment history, oncologist involvement, patient age, requested dose, and supporting evidence when applicable.
    Documentation Required

    Initial Authorization Documentation

    For initial authorization, submit documentation confirming that the patient meets all multiple myeloma approval criteria and provide the planned treatment details. Initial authorization is available for six months.

    Therapy Background

    BLENREP (belantamab mafodotin-blmf) is a B-cell maturation antigen (BCMA)-directed antibody and microtubule inhibitor conjugate used in adults with relapsed or refractory multiple myeloma after at least two prior lines of therapy, including a proteasome inhibitor and an immunomodulatory agent. Treatment requires attention to ocular, hematologic, and embryo-fetal risks, including verification of pregnancy status when applicable and ongoing clinical monitoring.

    Key Definitions

    BLENREP
    TermBLENREP
    Generic namebelantamab mafodotin-blmf
    DescriptionA B-cell maturation antigen (BCMA)-directed antibody and microtubule inhibitor conjugate.
    Relapsed or refractory multiple myeloma
    TermRelapsed or refractory multiple myeloma
    DefinitionMultiple myeloma that has returned after treatment or has not responded adequately to treatment.
    Policy populationAdults age 18 years or older with the diagnosis.

    Initial Therapy

    Initial Therapy Criteria

    Initial therapy is covered when all approval criteria are met:

    Initial BLENREP treatment

    • Covered indication: BLENREP is used for an adult patient with relapsed or refractory multiple myeloma after at least two prior lines of therapy, including a proteasome inhibitor and an immunomodulatory agent.Age ≥18 years; at least 2 prior lines
    • Administration setting: Treatment is provided as a physician-administered intravenous infusion in an office or hospital outpatient department; self-administration is not permitted.
    • Prescriber: Treatment is prescribed by or provided in consultation with an oncologist.

    Reauthorization and Continuation

    Reauthorization and Continuation

    Continuation may be authorized for 12 months. Treatment continues under the labeled regimen until disease progression or unacceptable toxicity:

    Reauthorization and continuation

    • Continue while clinically appropriate: Continue treatment while the disease has not progressed and toxicity remains acceptable.
    • Stop or modify for toxicity: Treatment may be delayed, reduced, or permanently discontinued based on the severity of adverse reactions.

    Prior Treatment Requirements

    StepPrior-therapy requirementSpecified prior agents
    1Before BLENREP coverage, the patient must have received at least two prior lines of multiple myeloma therapy, including both a proteasome inhibitor and an immunomodulatory agent.Proteasome inhibitors: bortezomib or Kyprolis. Immunomodulatory agents: pomalidomide or Revlimid.

    Dose and Quantity Limits

    BLENREP dosing and quantity limits
    Dose2.5 mg/kg
    Weight basisUsing actual body weight.
    Dosing intervalEvery three weeks (every 21 days).
    Combination regimenWith bortezomib and dexamethasone for eight cycles.
    After combination cyclesBLENREP 2.5 mg/kg every three weeks as a single agent.
    Treatment durationContinue until disease progression or unacceptable toxicity.

    Permitted Administration Settings

    Billing Rule

    Office administration only by physician

    In the office setting, administer BLENREP as a physician-administered IV infusion. Self-administration is not permitted.

    Billing Rule

    Hospital outpatient administration option

    BLENREP may be administered as a physician-administered IV infusion in a hospital outpatient department. It cannot be self-administered.

    Policy Summary
    PayerGold Coast Health Plan
    PolicyBLENREP (belantamab mafodotin-blmf) Coverage for Relapsed or Refractory Multiple Myeloma
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateFeb 12, 2026
    Last ReviewFeb 12, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization documentation confirming adult relapsed or refractory multiple myeloma, at least two prior therapy lines including a proteasome inhibitor and an immunomodulatory agent, and oncologist involvement.
    SourceLink
    On This Page
    BLENREP Coverage CriteriaBilling and CodingAuthorization and Documentation RequirementsTherapy BackgroundKey DefinitionsInitial TherapyReauthorization and ContinuationPrior Treatment RequirementsDose and Quantity LimitsPermitted Administration Settings
  1. Diagnosis of relapsed or refractory multiple myeloma.
  2. At least two prior lines of therapy, including a proteasome inhibitor and an immunomodulatory agent.
  3. Prescription by or consultation with an oncologist.
  4. Patient is age ≥ 18 years.
  5. Requested administration, dose, and treatment setting.
  6. Coverage duration: initial authorization six months; reauthorization 12 months.
  7. Documentation Required

    Off-Label Supporting Evidence

    For a relevant off-label use, the prescriber must submit supporting evidence showing that the requested dose or use is supported by applicable practice guidelines or peer-reviewed literature.

    • Include the applicable guideline citation or peer-reviewed publication with the request.
    • The evidence must support the requested off-label use and dose.
    Documentation Required

    Safety Monitoring Documentation

    Document required ocular and safety monitoring throughout treatment. BLENREP requires ophthalmic examination at baseline and before each dose, with prompt evaluation for new or worsening symptoms and additional evaluation as clinically indicated.

    • Maintain baseline and pre-dose ophthalmic examination documentation.
    • Document prompt assessment of new or worsening visual or ocular symptoms.
    • Monitor for thrombocytopenia and embryo-fetal toxicity; dose may be delayed, reduced, or permanently discontinued based on adverse-reaction severity.
    • Verify pregnancy status in females of reproductive potential before treatment and document contraception counseling as applicable.
    • Confirm participation in the BLENREP Risk Evaluation and Mitigation Strategy (REMS).
    Denial Risk

    Failure to Meet Multiple Myeloma Criteria

    Authorization is at denial risk when the request does not establish the required multiple myeloma diagnosis and treatment history.

    • Diagnosis is not relapsed or refractory multiple myeloma.
    • The patient has not received at least two prior lines of therapy.
    • Prior therapy does not include both a proteasome inhibitor and an immunomodulatory agent.
    • The request is not prescribed by or made in consultation with an oncologist.
    • The patient is younger than 18 years.
    Denial Risk

    Dose or Off-Label Support Not Met

    Authorization is at denial risk when the requested dose exceeds the stated limit and no accepted supporting evidence is submitted for the relevant off-label use.

    • Requested dose exceeds 2.5 mg/kg based on actual body weight every three weeks (21-day cycle).
    • For an off-label use, the prescriber does not submit practice-guideline or peer-reviewed-literature support.
    • The requested regimen is not consistent with FDA-approved labeling or accepted standards of medical practice.
    Billing Rule

    Administration Setting Requirement

    BLENREP must be administered as a physician-administered IV infusion in an office or hospital outpatient department (HOPD). It cannot be self-administered.

    • Administration: IV infusion by a physician.
    • Permitted settings: physician office or HOPD.
    • Self-administration is not permitted.
    Ocular toxicity
    TermOcular toxicity
    Corneal effectChanges in the corneal epithelium.
    Possible manifestationsVision changes, including severe visual impairment, blurred vision, dry eyes, and corneal ulcers.

    Dose or supported off-label use

    • FDA-labeled dosing: The dose does not exceed 2.5 mg/kg using actual body weight every three weeks, or every 21-day cycle.≤2.5 mg/kg actual body weight every 21 days
    • Relevant supported off-label use: The dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use, with supporting evidence submitted by the prescriber.